For postmenopausal women, hormone therapy with conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) for a median of 5.6 years or with CEE only for about 7.2 years was not associated with risk of all-cause, cardiovascular, or cancer mortality, according to new research. The observational followup involved more than 27,000 U.S. multiethnic postmenopausal women aged 50–79 years. In two randomized clinical trials, women received CEE plus MPA vs. placebo for 5.6 years or CEE alone vs. placebo for 7.2 years. During the cumulative 18-year followup, there were 1,088 deaths during the intervention phase and 6,401 deaths during postintervention followup. For the overall pooled cohort, all-cause mortality was 27.1% in the hormone therapy group compared with 27.6% in the placebo group. According to the data, 8.9% of women receiving hormone therapy and 9.0% of women receiving placebo died from cardiovascular disease, while the rates for total cancer mortality were 8.2% and 8.0%, respectively.